Skip to main content

Table 3 Prognostic factors for progression-free survival (PFS) and overall survival (OS) in multivariate analysis

From: Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

 

Baseline

PFS

OS

Adverse prognostic factor

HR [95%CI]

p value

HR [95%CI]

p value

Age < 65 years

2 [1.2–3.2]

0.007

N.S

≥ 3 lines of chemotherapy

3.2 [1.8–5.7]

< 0.0001

3.1 [1.3–7.6]

0.01

Baseline pTKa*

1.3 [1.1–1.4]

0.0005

1.3 [1.2–1.6]

< 0.0001

Performance status = 2

N.S

N.S

4.3 [1.3–13.5]

0.01

Synchronous metastasis

N.S

N.S

3.1 [1.3–7.5]

0.01

  1. *HR for an increase of 10 units of \( \sqrt{\mathrm{pTKa}} \)
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us